Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds
OtherClinical Investigations (Human)

Comparison of 11C-Pittsburgh compound-B and 18F-Flutemetamol White Matter Binding in PET

Burcu Zeydan, Christopher G Schwarz, Scott A Przybelski, Timothy G Lesnick, Walter K Kremers, Matthew L Senjem, Orhun H Kantarci, Paul H Min, Bradley J Kemp, Clifford R Jack, Kejal Kantarci and Val J Lowe
Journal of Nuclear Medicine December 2021, jnumed.121.263281; DOI: https://doi.org/10.2967/jnumed.121.263281
Burcu Zeydan
Mayo Clinic, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christopher G Schwarz
Mayo Clinic, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Scott A Przybelski
Mayo Clinic, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Timothy G Lesnick
Mayo Clinic, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Walter K Kremers
Mayo Clinic, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthew L Senjem
Mayo Clinic, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Orhun H Kantarci
Mayo Clinic, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul H Min
Mayo Clinic, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bradley J Kemp
Mayo Clinic, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Clifford R Jack Jr
Mayo Clinic, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kejal Kantarci
Mayo Clinic, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Val J Lowe
Mayo Clinic, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

PET imaging with β-amyloid ligands is emerging as a molecular imaging technique targeting white matter integrity and demyelination. β-amyloid PET ligands such as “11C-Pittsburgh compound-B” (11C-PiB) have been considered for quantitative measurement of myelin content changes in multiple sclerosis (MS), but 11C-PiB is not commercially available given its short half-life. A “18F-PET” ligand such as flutemetamol with a longer half-life may be an alternative, but its ability to differentiate white matter hyperintensities (WMH) from normal appearing white matter (NAWM) and its relationship with age remains to be investigated. Methods: Cognitively unimpaired (CU) older and younger adults (N = 61) were recruited from the community responding to a study advertisement for β-amyloid PET. Participants prospectively underwent MRI, 11C-PiB and 18F-Flutemetamol PET scans. MRI-FLAIR images were segmented into WMH and NAWM and registered to the T1-weighted MRI. 11C-PiB and 18F-Flutemetamol PET images were also registered to the T1-weighted image MRI. 11C-PiB and 18F-Flutemetamol standard uptake value ratios (SUVrs) from the WMH and NAWM were calculated using cerebellar crus uptake as a reference for both 11C-PiB and 18F-Flutemetamol. Results: Median age was 38 years (range 30-48) in younger adults and 67 years (range 61-83) in older adults. WMH and NAWM SUVrs were higher with 18F-Flutemetamol than 11C-PiB both in older (p<0.001) and in younger (p<0.001) CU adults. 11C-PiB and 18F-Flutemetamol SUVrs were higher in older compared to younger CU adults in both WMH (p<0.001) and in NAWM (p<0.001). 11C-PiB and 18F-Flutemetamol SUVrs were higher in NAWM compared to WMH in both older (p<0.001) and in younger (p<0.001) CU adults. There was no apparent difference between 11C-PiB versus 18F-Flutemetamol SUVrs in differentiating WMH from NAWM in older and in younger adults. Conclusion: 11C-PiB and 18F-Flutemetamol show a similar topographical pattern of uptake in white matter with a similar association with age in WMH and NAWM. 11C-PiB and 18F-Flutemetamol can also effectively distinguish between WMH and NAWM. However, given its longer half-life, commercial availability, and higher binding potential, 18F-Flutemetamol can be an alternative to 11C-PiB in molecular imaging studies specifically targeting MS to evaluate white matter integrity.

  • Neurology
  • PET
  • PET/CT
  • PET
  • Pittsburgh compound-B
  • flutemetamol
  • normal appearing white matter
  • white matter hyperintensity
  • Copyright © 2021 by the Society of Nuclear Medicine and Molecular Imaging, Inc.
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 63 (8)
Journal of Nuclear Medicine
Vol. 63, Issue 8
August 1, 2022
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Complete Issue (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Comparison of 11C-Pittsburgh compound-B and 18F-Flutemetamol White Matter Binding in PET
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Comparison of 11C-Pittsburgh compound-B and 18F-Flutemetamol White Matter Binding in PET
Burcu Zeydan, Christopher G Schwarz, Scott A Przybelski, Timothy G Lesnick, Walter K Kremers, Matthew L Senjem, Orhun H Kantarci, Paul H Min, Bradley J Kemp, Clifford R Jack, Kejal Kantarci, Val J Lowe
Journal of Nuclear Medicine Dec 2021, jnumed.121.263281; DOI: 10.2967/jnumed.121.263281

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Comparison of 11C-Pittsburgh compound-B and 18F-Flutemetamol White Matter Binding in PET
Burcu Zeydan, Christopher G Schwarz, Scott A Przybelski, Timothy G Lesnick, Walter K Kremers, Matthew L Senjem, Orhun H Kantarci, Paul H Min, Bradley J Kemp, Clifford R Jack, Kejal Kantarci, Val J Lowe
Journal of Nuclear Medicine Dec 2021, jnumed.121.263281; DOI: 10.2967/jnumed.121.263281
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Clinical Investigations (Human)

  • Static and dynamic 68Ga-FAPI PET/CT for the detection of malignant transformation of intraductal papillary mucinous neoplasia of the pancreas
  • Early-phase 18F-Florbetapir and 18F-Flutemetamol images as proxies of brain metabolism in a memory clinic setting
  • Optimized whole-body positron emission tomography magnetic resonance imaging sequence workflow in pediatric Hodgkin lymphoma patients
Show more Clinical Investigations (Human)

Clinical (Neurology)

  • Early-phase 18F-Florbetapir and 18F-Flutemetamol images as proxies of brain metabolism in a memory clinic setting
  • Alpha-synuclein PET and Parkinson’s Disease Therapeutic Trials: Ever the Twain Shall Meet?
  • High-resolution silicon photomultiplier time-of-flight dedicated head PET system for clinical brain studies
Show more Clinical (Neurology)

Similar Articles

Keywords

  • Neurology
  • PET
  • PET/CT
  • Pittsburgh compound-B
  • flutemetamol
  • normal appearing white matter
  • white matter hyperintensity
SNMMI

© 2022 Journal of Nuclear Medicine

Powered by HighWire